Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by spruleson Aug 08, 2013 9:34am
383 Views
Post# 21656328

BNC Ecoli damage fix 500k each

BNC Ecoli damage fix 500k eachhttps://metronews.ca/news/ottawa/760014/life-changing-drug-may-be-denied-to-patients-on-500000-cost/




https://en.wikipedia.org/wiki/Eculizumab
https://en.wikipedia.org/wiki/Eculizumab

STEC-HUS[edit source | edit]

There are case reports of eculizumab being used to treat Shiga-toxin-producing Escherichia colihemolytic-uremic syndrome (STEC-HUS),[30] such as occurred during the May 2011 outbreak of enteroaggretative E. coli infections in Germany (the STEC-HUS commonly seen in North America is of the enterohemorrhagic type). Eculizumab was given to block complement activation, which plays a role in the pathogenesis of both STEC-HUS and aHUS. Specifically, Shiga-toxin has been shown to trigger uncontrolled complement activity through direct activation of the alternative complement pathway[31][32] as well as by binding to and inactivating the regulatory protein complement factor H.[33]

<< Previous
Bullboard Posts
Next >>